Facebook Linkedin RSS Twitter Youtube
Home 2024

Ulcerative colitis

Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs
Drug Discovery

Lilly to Acquire Morphic for $3.2B, Adding Phase II IBD Programs

Inflammatory Diseases Kindled When HDAC Proteins Act on Th17 Cells
News

Inflammatory Diseases Kindled When HDAC Proteins Act on Th17 Cells

CAR and Mesenchymal Stromal Cells Combine to Enhance Autoimmune Disease Immunotherapy
News

CAR and Mesenchymal Stromal Cells Combine to Enhance Autoimmune Disease Immunotherapy

With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate
Artificial Intelligence

With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate

Insilico Doses First Patient with AI-Designed IBD Treatment
Artificial Intelligence

Insilico Doses First Patient with AI-Designed IBD Treatment

Abivax Advances Ulcerative Colitis Candidate with U.S. IPO
Drug Discovery

Abivax Advances Ulcerative Colitis Candidate with U.S. IPO

Roche to Acquire Telavant for Up-to-$7.25B, Adding IBD Antibody
Drug Discovery

Roche to Acquire Telavant for Up-to-$7.25B, Adding IBD Antibody

StockWatch: Novo Nordisk Shares Soar as Ozempic Aces Phase III CKD Trial
Drug Discovery

StockWatch: Novo Nordisk Shares Soar as Ozempic Aces Phase III CKD Trial

Peptides Developed to Diagnose Common Inflammatory Diseases
News

Peptides Developed to Diagnose Common Inflammatory Diseases

Merck to Acquire Prometheus Biosciences for $10.8B
Drug Discovery

Merck to Acquire Prometheus Biosciences for $10.8B

123...7Page 1 of 7
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.